

QUARTERLY UPDATE

Q3 2023 | OCTOBER 2023















4 Myths about alternative proteins

1. Fermentation is only useful to produce beer, kombucha and yogurts

Fermentation has historically been used to produce beer and yogurts, but new, more engineered end uses are now being developed with precision fermentation. By modifying microorganisms, companies have been able to create high protein, high fiber ingredients that can enhance plant-based alternatives, but also cruelty-free dairy proteins. Such ingredients account for roughly 12% of the ingredients market and a limited portion of plantbased alternatives, but penetration could increase sharply as products obtain regulatory approval.

2. Mushrooms are only a great addition to my risotto

Mushrooms, or more specifically fungi, has been used for over 40 years to produce mycoprotein, a protein and fiber rich product similar to tempeh or tofu. Although Quorn has been leading the market, new players are entering the field with direct-to-consumer products and ingredients that can be used to produce hybrid plant-based alternatives with better taste and enhanced nutritional profile.



Luxury companies, in particular Kering, are also showing a growing interest in fungi derived leather alternatives and working with key players in the space, as shown by the collaboration between SQIM and Balenciaga.

3. Cultivated meat is not really meat

Cultivated meat has exactly the same nutritional properties, taste and texture as conventional meat. Companies have been working hard to find the perfect growth media formulation to grow a bifteck or chicken breast and clients who've tried it so far (in the US) confirm! Not only do companies look at meat, but also seafood, fat and even leather replication: the cultivated protein landscape offers an unlimited set of opportunities supported by a rapidly evolving regulatory landscape.

4. There are limited investment opportunities in the space

Although fermentation, mycoprotein and cultivated meat have attracted over EUR5bn of investment since 2020, financing needs and opportunities remain in the space. On one side Venture Capitalists will find great novel companies in Europe that need support to reach pilot plant. On another side, later stage investors might want to contribute funding the USD5-12bn CAPEX investments required in the space by 2030. Even large corporates in the food and ingredients space.







Food & Nutrition Analyst BG IRIS



Energy Transition & Sustainability

Banking for a better future

Leadership



Olivier Beaudouin Partner, Head of Industrial Tech, Energy Transition & Sustainability

Amid a volatile market environment, we see several reasons to remain optimistic about the future. Climate-focused funds have continued building their AuM, resulting in a significant pile of dry powder earmarked for climate tech investment. The IRA has given a new impetus to the market in the US and beyond.

Finally, while investors have become more demanding on valuation and route to profitability, several landmark transactions have been successfully closed, demonstrating that climate and sovereignty-driven opportunities remain potent themes, notably in verticals like recycling (notably plastics) and circularity, batteries, or rare earths.

Key figures



Selected Deals

CARBIOS	Hydrogen pro	eve.	SHARK'
Rights Issue	Follow-on Offering	Acquired by	Private Placement
	🐞 OSLO BØRS NOK 126 000 000	ABB Undisclosed	
bint Global Coordinator & Joint Bookrunner	Joint Global Coordinator & Joint Bookrunner	Sole Financial Advisor to the Sellers	€ 20 000 000 Financial Advisor
ite Papers			

Healthcare

Backing innovation in Healthcare

Leadership



Hervé Ronin Partner, Head of Healthcare



Alex Cogut Head of Healthcare Research, BG IRIS

It was a challenging quarter for the market with healthcare indices trading down in line with the general indices as macro-economic uncertainty persisted. That said, it was an unusually robust quarter for public capital raises for European healthcare companies on the back of strong clinical data or following growth pockets in the healthcare services segment.

However, healthcare M&A activity was globally one of the lowest in recent years in terms of value but rebounded in transactions volume. In biopharma, we saw a continuation of a well established pattern by now of big pharma acquiring clinically derisked or commercial stage biotechs.

Key figures



Selected Deals

EGETIS THERAPEUTICS PIPE & Debt Financing	Structured Debt Financing	Follow-on Offering & Convertible bonds issuance	PhysioAssist Acquired by
SEK 462 000 000	€ 150 000 000	€ 21 600 000	\$ 45 000 000 (Pending)
Sole Global Coordinator & Sole Bookrunner	Sole Advisor & Sole Placement Agent	Sole Global Coordinator & Sole Bookrunner	Sole Financial Advisor to the Company and its Shareholders





Q3 2023 | QUARTERLY UPDATE



Software & FinTech

Delivering for our clients through challenging times

Leadership



Acknowledging high but stabilised interest rates, investors in public and private equity remain keen on paying premium valuations to high-performing software vendors.

Thibaut De Smedt Partner, Co-Head of Software & FinTech



Stanislas de Gmeline Partner, Co-Head of Software & FinTech On the fintech industry, although valuation multiples are nearing an all-time-low, public market investors continue shunning the sector. The deterioration in financing conditions and consumer spending cast a shadow on near term prospects while commoditisation risks put further pressure on sub-scaled players. In that context, fintech companies are natural takeover opportunities for private equity investors.

Key figures



Selected Deals

nels DIGITAL xperis	EXPLORE DATA FOR SUCCESS	Sinari	KEENSIGHT
Acquired by	Acquired by	Acquired by	Investment in
🗲 enovacom	INTESCIA		
Subsidiary of	Portfolio company of	Bridgepoint	-Attestations
Business	Five Arrows		
_		Undisclosed	Undisclosed
Sole Financial Advisor to the Sellers	Sole Financial Advisor to the Sellers	July 2023 Sole Financial Advisor to the Sellers	July 2023 Financial Advisor to the Buyer



Investors aim for the stars

The space challenges

Space has emerged as a notable investment category, drawing capital inflows of tens of billions of dollars since the beginning of NewSpace. Nevertheless, the challenges of investing in space were apparent during a tumultuous 2022. That year was characterized by a more stringent capital environment and the collapse of growth-oriented technological stocks, with a particular impact on Special Purpose Acquisition Companies (SPACs).

Greater market potential

However, the space sector demonstrated commendable resilience. Investment within this sphere experienced a slower rate of decline compared to the global tech industry. Aeronautics and Space stocks managed to outperform the broader market. While space-based valueadded services, distinguished by their greater market potential and lower capital intensity, continue to exude strong appeal, our contention is that upstream markets, although often narrower and fragmented, can also be highly attractive due to robust government support.

Increased M&A activity

We anticipate an increasing number of M&A deals to take place in the coming months and years, although transaction activity in the New Space sector has recently been mainly financing oriented.



Consolidation will mainly take place between complementary players resulting in the emergence of category leaders which will become much more relevant for later stage investors, or perhaps even for public markets investors.

Lack of additional required funding may also force certain entrepreneurs to accelerate their M&A plans. Lastly, Satellite incumbents are undoubtedly expected to take an active role by adding innovative capabilities to their existing core offerings.

A record year

The spacetech M&A is witnessing an all-time high, primarily driven by well-capitalised 'New Space' acquirers. Space deals in the twelve months leading to Q3 2023 have increased by 45% yearon-year. When putting this trend in the current M&A context, we cannot help but notice that investors are indeed aiming for the stars.





Roulet Partner

London

Florent



Thomas Coudry

Head of Tech Research BG IRIS



Antoine Lebourgeois

Associate BG IRIS



BRYAN. GARNIER & CO

Industrial Tech

Automating industries

Leadership



We're witnessing a resurgence in midmarket M&A as companies embark on strategic transformations to accelerate their growth.

Olivier Beaudouin Partner, Head of Industrial Tech, Energy Transition & Sustainability

The market is displaying resilience, particularly for cash-rich corporate acquirers and mid-market transactions. We also denote a steady increase in business owners' willingness to transact in 2024.

Key figures



Selected Deals





Q3 2023 | QUARTERLY UPDATE



IT Engineering - Business & Tech-Enabled Services

A resilient sector

Leadership



Guillaume NathanFPartner,tHead of Business & Tech-EnabledsServicess

 Investor interest in IT and Engineering Services firms stays high, since digital transformation and the development of products which include more digital content remain top priorities for organisations. Private equity investors are still actively investing in the sector, although they are increasingly selective in the quality and the potential of their investment.

> Finally, M&A momentum is still there, driven by the needs of potential acquirers for additional capacity in targeted areas, provided that sellers are less demanding on valuation.

Key figures +40Transactions in the last 3 years €1.5bn Deal value since initiation 75% Sell-side M&A with trade buyers 5 **Equity Analysts**

Selected Deals

rts₽	iplan	າໝາ 🏐	Canon
Acquired by and annia Backed by Kingson K Partners Two reparts	Acquired by	Private Placement Marondo 🍑 TGFS bm{t	Sold Canton to PARAGEN
Sole Advisor to the Seller	Sole Financial Advisor to the Buyer	Sole Financial Advisor	Sole Financial Advisor to the Seller



BRYAN, GARNIER & CO

THE **EUROPEAN GROWTH** INVESTMENT BANK

London

16 Old Oueen Street London SW1H 9HP UK T: +44 20 7332 2500

Stockholm

Nybrokajen 5 111 48 Stockholm Sweden T: +46 722 40 10 80

Paris 92. Avenue des Champs-Elysées 75008 Paris T: +33 1 56 68 75 00

Beddingen 8, Aker

Brygge Postbox: 0117

Oslo 0250 - Norway

T: +47 22 01 64 00

Oslo

Oslo

80539 Munich Germany T: +49 89 242 262 11

Munich

Königinstraße 9

Amsterdam

Strawinskylaan 4117 1077 ZX Netherlands

New-York

750 Lexington Avenue New York, NY 10022 USA T: +1 212 337 7000

Our Website



